Innovative Research to Advance Oligonucleotide Therapeutics now published in the Journal of Nucleic Acid Therapeutics | Newswise

Innovative Research to Advance Oligonucleotide Therapeutics now published in the Journal of Nucleic Acid Therapeutics | Newswise

Newswise — LIMERICK, Pa., Feb. 25, 2025 /PRNewswire/ — Rockland Immunochemicals, Inc. is pleased to announce that Dr. David P. Chimento, Vice President of Research and Development, Amy L. Anderson, Technical Applications Specialist, and Dr. Carl Ascoli, Chief Science Officer, working with Inês Fial, Research Assistant at the Nucleic Acid Therapeutics Accelerator (NATA, Oxford, United Kingdom), have…

Read More
Huxley Medical Announces FDA Clearance for Cellular-Enabled SANSA Home Sleep Apnea Test | Newswise

Huxley Medical Announces FDA Clearance for Cellular-Enabled SANSA Home Sleep Apnea Test | Newswise

Newswise — Feb. 5, 2025  Huxley Medical, a commercial-stage medical technology firm focused on streamlining detection of sleep and heart disorders, announced that the US Food and Drug Administration (FDA) has cleared the SANSA home sleep apnea test to begin using cellular data upload capabilities. This breakthrough eliminates the need for Bluetooth pairing or smartphone apps…

Read More
Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of 0 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader | Newswise

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader | Newswise

Newswise — BEDFORD, Mass., Jan. 28, 2025 /PRNewswire/ — Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a definitive agreement to acquire Evergreen Theragnostics, Inc. (“Evergreen”), in an all-cash transaction consisting of an upfront payment of…

Read More
Aptitude Secures M+ to Accelerate Development o | Newswise

Aptitude Secures $10M+ to Accelerate Development o | Newswise

Newswise — SANTA BARBARA, Calif., Jan. 6, 2025 — Aptitude Medical Systems, Inc. (Aptitude) has secured funding from the Bill & Melinda Gates Foundation to accelerate the development and release of its new Point of Care (POC) and Over-The-Counter (OTC) Chlamydia, gonorrhea, and trichomoniasis sexually transmitted infection (STI) test on the Metrix® molecular diagnostics platform. The…

Read More
UCSF-led Study Aims to Improve Treatment of Painfu | Newswise

UCSF-led Study Aims to Improve Treatment of Painfu | Newswise

  Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition that disproportionately affects women and people of color. It begins in adolescence and can be debilitating, negatively impacting sufferers’ quality of life, physical function, work productivity and social and emotional wellbeing. Unfortunately, it is also poorly understood and understudied both clinically and biologically, although it…

Read More